Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3048% below fair value
$2.96−0.17 (-5.43%)
Close on Nov 12, 2026Market cap $238.49MP/E 11.8Yield –
Protalix BioTherapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Protalix BioTherapeutics's profit margin for the twelve months ending Sep 30, 2026 was 24.3%. For fiscal 2025 it was -12.5%, against 5.5% the year before. The highest annual figure on record is 1329.9% in fiscal 2015.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -12.5% | −18.0 |
| FY2024 | Dec 31, 2024 | 5.5% | −7.2 |
| FY2023 | Dec 31, 2023 | 12.7% | +44.0 |
| FY2022 | Dec 31, 2022 | -31.3% | +40.6 |
| FY2021 | Dec 31, 2021 | -71.9% | −61.6 |
| FY2020 | Dec 31, 2020 | -10.4% | +23.0 |
| FY2019 | Dec 31, 2019 | -33.4% | +43.9 |
| FY2018 | Dec 31, 2018 | -77.3% | +318.6 |
| FY2017 | Dec 31, 2017 | -395.9% | −76.6 |
| FY2016 | Dec 31, 2016 | -319.2% | −1649.1 |
| FY2015 | Dec 31, 2015 | 1329.9% | +2179.8 |
| FY2014 | Dec 31, 2014 | -849.9% | −816.6 |
| FY2012 | Dec 31, 2012 | -33.3% | +402.3 |
| FY2011 | Dec 31, 2011 | -435.6% | +1.0 |
| FY2010 | Dec 31, 2010 | -436.6% | +7666.5 |
| FY2009 | Dec 31, 2009 | -8103.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 18.1% | +4.9 |
| Q2 FY2026 | Jun 30, 2026 | 19.0% | +17.9 |
| Q1 FY2026 | Mar 31, 2026 | 54.3% | +90.1 |
| Q4 FY2025 | Dec 31, 2025 | -60.3% | −96.0 |
| Q3 FY2025 | Sep 30, 2025 | 13.2% | −4.8 |
| Q2 FY2025 | Jun 30, 2025 | 1.0% | +17.4 |
| Q1 FY2025 | Mar 31, 2025 | -35.8% | +86.8 |
| Q4 FY2024 | Dec 31, 2024 | 35.6% | +93.3 |
| Q3 FY2024 | Sep 30, 2024 | 18.0% | +35.9 |
| Q2 FY2024 | Jun 30, 2024 | -16.4% | −71.5 |
| Q1 FY2024 | Mar 31, 2024 | -122.6% | −89.9 |
| Q4 FY2023 | Dec 31, 2023 | -57.6% | −14.2 |
| Q3 FY2023 | Sep 30, 2023 | -17.9% | +7.2 |
| Q2 FY2023 | Jun 30, 2023 | 55.1% | +116.1 |
| Q1 FY2023 | Mar 31, 2023 | -32.7% | −18.4 |
| Q4 FY2022 | Dec 31, 2022 | -43.4% | +34.6 |
| Q3 FY2022 | Sep 30, 2022 | -25.1% | +9.7 |
| Q2 FY2022 | Jun 30, 2022 | -60.9% | +114.0 |
| Q1 FY2022 | Mar 31, 2022 | -14.2% | +34.2 |
| Q4 FY2021 | Dec 31, 2021 | -78.0% | −80.0 |
| Q3 FY2021 | Sep 30, 2021 | -34.8% | −42.5 |
| Q2 FY2021 | Jun 30, 2021 | -174.9% | −176.5 |
| Q1 FY2021 | Mar 31, 2021 | -48.4% | −23.4 |
| Q4 FY2020 | Dec 31, 2020 | 2.0% | +65.3 |
| Q1 FY2020 | Mar 31, 2020 | 7.7% | +77.3 |
| Q4 FY2019 | Dec 31, 2019 | 1.6% | +21.8 |
| Q3 FY2019 | Sep 30, 2019 | -25.0% | +777.7 |
| Q2 FY2019 | Jun 30, 2019 | -63.2% | +358.6 |
| Q1 FY2019 | Mar 31, 2019 | -69.6% | +89.4 |
| Q4 FY2018 | Dec 31, 2018 | -20.1% | +288.9 |
| Q3 FY2018 | Sep 30, 2018 | -802.7% | −650.7 |
| Q2 FY2018 | Jun 30, 2018 | -421.8% | −428.9 |
| Q1 FY2018 | Mar 31, 2018 | -159.0% | +1888.4 |
| Q4 FY2017 | Dec 31, 2017 | -309.1% | −183.0 |
| Q3 FY2017 | Sep 30, 2017 | -152.0% | +4.1 |
| Q2 FY2017 | Jun 30, 2017 | 7.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -2047.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -126.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -156.1% | – |
See a number that looks wrong?